Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone, Merck KGaA deal

IMCLE received a $6 million equity investment from MRK triggered

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE